Atlas Trials

Neuroendocrine Carcinoma, Grade 3

2 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Neuroendocrine Carcinoma, Grade 3

RecordFirmDate
Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes (NCT03147404)Samsung Medical Center2017-12-28
Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study (NCT02113800)AIO-Studien-gGmbH2015-08-01

Track Neuroendocrine Carcinoma, Grade 3 automatically

Every clearance here is in the API, with alerts when new ones post.